About this trial
The endocannabinoid system (ECS) is a complex endogenous signaling system made up of transmembrane cannabinoid receptors (CB1 and CB2 receptors), their endogenous lipid-derived ligands (the endocannabinoids - eCBs), and enzymes for ligand biosynthesis and degradation. Interestingly, exercise increase plasma AEA, one of the most famous endocannabinoid. This increase could be involved in exercise-induced neurogenesis and other beneficial exercise adaptations. Chronic cannabis use is associated with alteration of ECS activity. The aim of the study is to compare ECS response to exercise between chronic cannabis users and non-users.
Eligibility criteria
Qualifiers
Cannabis consumption > 100 times in lifetime, last exposure < 7 days, and recent exposure > 10 times in the month.
Positive toxicological urine test for ∆-9-THC.
Having a cannabis use disorder according to the CAST.
Negative urine toxicological test for cannabis.
Disqualifiers
Disorders of use of other substances (alcohol, cocaine, opioid, or synthetic drugs).
Alcohol consumption greater than 30g per day (averaged over one week) and/or alcohol abuse the week preceding the visit.
Under medical treatment.
Presence of diagnosed neurological disorders.
Trial design
Treatments tested in this trial
- activity test